engleski

Plasminogen activator inhibitor-1 genotype distribution in stroke patients

Plasminogen activator inhibitor-1 (PAI-1) is a serine protease that regulates fibrinolysis through inhibition of t-PA and u-PA. The PAI-1 4/5 – guanine (4G/5G) polymorphism in promoter region affects PAI-1 gene transcription due to different binding of transcription regulating proteins. A 4G allele has been reported to be associated with increased PAI-1 activity, resulting in impaired endogenous fibrinolytic function and predisposition to thrombosis. Many studies showed that 4G5G polymorphism is associated with increased risk for cardiovascular disease. Still, conflicting data are reported for cerebrovascular disease, even suggesting protective role of 4G allele. In order to investigate relation between 4G5G polymorphism and stroke incidence, 52 stroke patients (27 male, 25 female) and 126 healthy subjects (83 male, 43 female) were genotyped by PCR-SSCP analysis. Genotype distribution among controls was: 4G4G 24% (30/126), 4G5G 48% (60/126) and 5G5G 29% (36/126). The allelic frequencies in control group were: 4G 48% and 5G 52%. In patients group the genotype distribution was: 4G4G 23% (12/52), 4G5G 40% (21/52) and 5G5G 37% (19/52). The frequencies for 4G and 5G alleles were 43% and 57%, respectively. There was no significant difference for genotype and allele frequencies between patient and control group (÷2 test). A trend towards a lower prevalence of the 4G allele in the patients group was observed (43% vs. 48% in control group, OR 0.8, 95% CI 0.53-1.32). These preliminary findings suggest that 4G allele is not a risk factor for stroke incidence. Further studies are needed on a larger number of subjects to evaluate the role of 4G allele in cerebrovascular disease.

plasminogen activator inhibitor-1; genotyping; stroke

nije evidentirano